Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 5Phase 1 4Phase 3 3Phase 2/3 3Phase NA 2Phase 4 2

Status

Completed 164Active not recruiting 47Recruiting 45Unknown 35Terminated 27Withdrawn 5Not yet recruiting 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Paclitaxel 24Oxaliplatin 24Capecitabine 24Gemcitabine 21Cisplatin 21Fluorouracil 20Drug Therapy 18Docetaxel 18Carboplatin 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Specimen Handling 9Pemetrexed 9Radiation 8Injections 8Cetuximab 8toripalimab 7Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6Trastuzumab 6Topotecan 6Standard of Care 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Dexamethasone × Clear all
NCT07285239 2026-05-18

PrE1005

PrECOG, LLC.

Phase 3 Not yet recruiting
500 enrolled
Plasma cell

Multiple Myeloma

NCT07569757 2026-05-08

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
260 enrolled
Plasma cell

Multiple Myeloma

NCT06742138 2024-12-19

To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

Qilu Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
284 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡